BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma

[1]  R. Polosa,et al.  Non-occupational malignant pleural mesothelioma due to asbestos and non-asbestos fibres. , 2016, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[2]  M. Speicher,et al.  Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Pass,et al.  BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs , 2012, Journal of Translational Medicine.

[4]  M. Ladanyi,et al.  New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment , 2012, Clinical Cancer Research.

[5]  M. Emi,et al.  Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma , 2012, Cancer science.

[6]  F. Mott.  Mesothelioma: a review. , 2012, The Ochsner journal.

[7]  M. Abdel-Rahman,et al.  Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers , 2011, Journal of Medical Genetics.

[8]  J. Becker,et al.  Germline mutations in BAP1 predispose to melanocytic tumors , 2011, Nature Genetics.

[9]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[10]  C. Sander,et al.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma , 2011, Nature Genetics.

[11]  A. Bowcock,et al.  Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas , 2010, Science.

[12]  Anindya Dutta,et al.  The Deubiquitinating Enzyme BAP1 Regulates Cell Growth via Interaction with HCF-1* , 2009, The Journal of Biological Chemistry.

[13]  D. Fennell,et al.  Malignant pleural mesothelioma: current treatments and emerging drugs , 2009, Expert opinion on emerging drugs.

[14]  S. Gygi,et al.  Defining the Human Deubiquitinating Enzyme Interaction Landscape , 2009, Cell.

[15]  A. Cesario,et al.  Osteopontin is not a specific marker in malignant pleural mesothelioma. , 2009, The International journal of biological markers.

[16]  R. Flores.  Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication. , 2009, Seminars in thoracic and cardiovascular surgery.

[17]  J. Neuzil,et al.  Malignant mesothelioma: biology, diagnosis and therapeutic approaches. , 2009, Current molecular pharmacology.

[18]  R. Stahel,et al.  Functional inactivation of NF2/merlin in human mesothelioma. , 2009, Lung cancer.

[19]  V. Dixit,et al.  Association of C-Terminal Ubiquitin Hydrolase BRCA1-Associated Protein 1 with Cell Cycle Regulator Host Cell Factor 1 , 2009, Molecular and Cellular Biology.

[20]  F. Galateau-Sallé,et al.  Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas , 2008, Virchows Archiv.

[21]  Erwin G. Van Meir,et al.  BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. , 2008, Cancer research.

[22]  V. Seshan,et al.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. , 2008, The Journal of thoracic and cardiovascular surgery.

[23]  Ji Luo,et al.  Cancer Proliferation Gene Discovery Through Functional Genomics , 2008, Science.

[24]  A. Hyman,et al.  Genome-scale RNAi profiling of cell division in human tissue culture cells , 2007, Nature Cell Biology.

[25]  Cindy B. Yeoh,et al.  Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  T. Treasure,et al.  Pleural mesothelioma: little evidence, still time to do trials , 2004, The Lancet.

[27]  Biao He,et al.  SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Ladanyi,et al.  Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  C. Vandenberg,et al.  Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains , 2002, The EMBO journal.

[30]  K. Uematsu,et al.  Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. , 2002, Molecular cancer therapeutics.

[31]  G. Gordon,et al.  Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. , 2002, Carcinogenesis.

[32]  G. Melloni,et al.  Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. , 2001, Lung cancer.

[33]  D. Jensen,et al.  BAP1, a Candidate Tumor Suppressor Protein That Interacts with BRCA1 , 1999, Annals of the New York Academy of Sciences.

[34]  Keith D Wilkinson,et al.  BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression , 1998, Oncogene.

[35]  S. Neragi-Miandoab.  Multimodality approach in management of malignant pleural mesothelioma. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[36]  J Espinosa Arranz,et al.  [Malignant mesothelioma]. , 1994, Medicina clinica.